Neoprobe's largest investor to drop proxy fight threat

Neoprobe has reached an agreement with Platinum Montaur Life Sciences regarding the nomination of directors. As a result of the agreement, Peter Drake and Jess Emery Jones will fill two current board vacancies with terms expiring at the 2012 annual meeting. Both also will be nominated for election as directors for terms expiring at the company's 2014 annual meeting. Platinum had been pushing for adding more biotech expertise to the board. Neoprobe release | Story

Suggested Articles

The spine surgery company ATEC has moved to acquire Paris-based EOS imaging, makers of FDA-cleared scanners and 3D orthopedic planning software.

Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer.

Ortho Clinical Diagnostics has launched a new chemistry system to complete its integrated Vitros XT line of laboratory solutions.